Skip to Content

Nanosonics Ltd NAN

Morningstar Rating
A$2.83 −0.09 (3.08%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Shares in Nanosonics Screen As Undervalued

Nanosonics’ Trophon solution for high-level disinfection of ultrasound probes has garnered substantial market share, evidenced by penetration of over 75% in Australia and New Zealand and 40% in North America. We expect elevated growth over the next three years as Trophon continues to gain share in North America and launch in Japan, but high market penetration may be more challenging to achieve in developing economies, which may not be able to prioritize nuanced disinfection standards. Moreover, the device patent expires in 2025, leading to slower volume growth in the medium term.

Price vs Fair Value

NAN is trading at a 27% discount.
Price
A$2.92
Fair Value
A$2.00
Uncertainty
High
1-Star Price
A$3.40
5-Star Price
A$9.20
Economic Moat
Lqlkhr
Capital Allocation
Gkpbhlwsg

Bulls Say, Bears Say

Bulls

Nanosonics is the market leader in automated HLD of ultrasound probes with significant further market penetration potential in most regions.

Bears

Nanosonics is a single-product company with a pipeline product that is largely unproven.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NAN is a good fit for your portfolio.

Trading Information

Previous Close Price
A$2.92
Day Range
A$2.832.91
52-Week Range
A$2.595.73
Bid/Ask
A$2.83 / A$2.85
Market Cap
A$857.43 Mil
Volume/Avg
636,447 / 1.4 Mil

Key Statistics

Price/Earnings (Normalized)
56.52
Price/Sales
5.41
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Nanosonics is a single-product firm and its Trophon device provides high-level disinfection of ultrasound probes used in semicritical procedures. The patented technology uses low-temperature sonically activated hydrogen peroxide mist suitable for probes sensitive to damage. Automated HLD is increasingly being used as the standard of care globally as it is superior in preventing cross-infection of patients. Nanosonics’ revenue is made up of capital sales of Trophon units, ongoing consumables sales, and service revenue. By June 2022, there were 29,850 Trophon units installed globally. Market penetration rates range from over 75% in Australia and New Zealand, about 44% in the U.S. to low-single-digit penetration in Europe, Middle East, and Africa, and elsewhere in the Asia-Pacific region.
Sector
Healthcare
Industry
Medical Instruments & Supplies
Stock Style Box
Small Growth
Total Number of Employees
400

Competitors

Valuation

Metric
NAN
RMD
FPH
Price/Earnings (Normalized)
56.5229.7962.01
Price/Book Value
5.046.799.46
Price/Sales
5.416.959.73
Price/Cash Flow
37.1425.0242.35
Price/Earnings
NAN
RMD
FPH

Financial Strength

Metric
NAN
RMD
FPH
Quick Ratio
5.261.321.06
Current Ratio
6.563.042.54
Interest Coverage
12.4622.6325.77
Quick Ratio
NAN
RMD
FPH

Profitability

Metric
NAN
RMD
FPH
Return on Assets (Normalized)
9.04%15.75%12.48%
Return on Equity (Normalized)
11.94%24.94%16.75%
Return on Invested Capital (Normalized)
9.96%19.33%15.46%
Return on Assets
NAN
RMD
FPH
See how this stock stacks up to its competitors with Morningstar Investor

Medical Instruments & Supplies Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
ISRG
Intuitive Surgical IncNzmnrmgxkkYtp$131.5 Bil
BDX
Becton Dickinson & CoJnbckthplChdwrms$67.8 Bil
ALC
Alcon IncNgfvxtjytJplwz$38.5 Bil
RMD
ResMed IncWncrmvkyFfvkwhn$31.4 Bil
CLPBY
Coloplast A/S ADRBzkyqqhsxMdxr$27.3 Bil
WST
West Pharmaceutical Services IncWrrzqhwglKgcvs$26.2 Bil
BAX
Baxter International IncZbvlsbjWtmgf$20.6 Bil
HOLX
Hologic IncNgcckgmfBtddyd$17.8 Bil
COO
The Cooper Companies IncGdwqbynhXhwlrn$17.7 Bil
TFX
Teleflex IncWpmtVgnp$9.8 Bil

Sponsor Center